Table 1.
Patient characteristics (N=202)
| Demographic characteristics | |
| Average age (SD) | 68.8 (7.0) |
| 60–69 years | 62.2% |
| 70–79 years | 28.9% |
| ≥80 years | 8.9% |
| Male | 99.0% |
| White | 84.1% |
| Black | 10.9% |
| Other race | 5.0% |
| Employed | 14.9% |
| Annual household income >$40,000 | 31.8% |
| College graduate | 17.9% |
| Excellent or very good health status | 15.9% |
| Good health status | 42.8% |
| Fair or poor health status | 41.3% |
| Clinical characteristics | |
| History of upper gastrointestinal event | 6.5% |
| History of cerebrovascular accident | 10.4% |
| History of myocardial infarction | 24.9% |
| Transient ischemic attack | 6.5% |
| Coronary artery disease | 85.1% |
| PCI/CABG | 40.3% |
| Medication characteristics | |
| Current use of ACAP | 0.5% |
| Current use of ASAC | 33.8% |
| Current use of ASAP | 57.2% |
| Current use of TRIP | 8.5% |
| CAT duration <2 years | 24.4% |
| CAT duration 3–5 years | 29.3% |
| CAT duration >5 years | 46.3% |
| NSAID use | 9.5% |
| SSRI use | 18.9% |
| PPI use | 31.3% |
| H2-receptor blocker use | 18.4% |
Abbreviations: SD, standard deviation; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CAT, complex antithrombotic therapy; ACAP, combination therapy with anticoagulant and antiplatelet agent; ASAC, combination therapy with aspirin and anticoagulant; ASAP, combination therapy with aspirin and antiplatelet agent; TRIP, combination therapy with aspirin, antiplatelet agent and anticoagulant; NSAID, nonsteroidal anti-inflammatory drug; SSRI, selective serotonin reuptake inhibitor; PPI, proton pump inhibitor.